AU2020210831B2 - Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity - Google Patents

Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity Download PDF

Info

Publication number
AU2020210831B2
AU2020210831B2 AU2020210831A AU2020210831A AU2020210831B2 AU 2020210831 B2 AU2020210831 B2 AU 2020210831B2 AU 2020210831 A AU2020210831 A AU 2020210831A AU 2020210831 A AU2020210831 A AU 2020210831A AU 2020210831 B2 AU2020210831 B2 AU 2020210831B2
Authority
AU
Australia
Prior art keywords
polymorph
lloq
pain
dose
coen4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020210831A
Other languages
English (en)
Other versions
AU2020210831A1 (en
Inventor
Robert Hett
Eli Kaplan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novaremed Ag
Original Assignee
Novaremed Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaremed Ag filed Critical Novaremed Ag
Publication of AU2020210831A1 publication Critical patent/AU2020210831A1/en
Assigned to Novaremed AG reassignment Novaremed AG Amend patent request/document other than specification (104) Assignors: NOVAREMED LTD.
Application granted granted Critical
Publication of AU2020210831B2 publication Critical patent/AU2020210831B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/22—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2020210831A 2019-01-23 2020-01-22 Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity Active AU2020210831B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19153315.7 2019-01-23
EP19153315 2019-01-23
PCT/EP2020/051528 WO2020152226A1 (en) 2019-01-23 2020-01-22 Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity

Publications (2)

Publication Number Publication Date
AU2020210831A1 AU2020210831A1 (en) 2021-05-20
AU2020210831B2 true AU2020210831B2 (en) 2025-02-13

Family

ID=65228356

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020210831A Active AU2020210831B2 (en) 2019-01-23 2020-01-22 Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity

Country Status (17)

Country Link
US (1) US11891350B2 (enExample)
EP (1) EP3860582B1 (enExample)
JP (2) JP7611148B2 (enExample)
KR (1) KR20210119403A (enExample)
CN (1) CN113329746B (enExample)
AU (1) AU2020210831B2 (enExample)
BR (1) BR112021019476A2 (enExample)
CA (1) CA3118996A1 (enExample)
DK (1) DK3860582T3 (enExample)
ES (1) ES2913977T3 (enExample)
IL (1) IL282718B2 (enExample)
PL (1) PL3860582T3 (enExample)
PT (1) PT3860582T (enExample)
RS (1) RS63270B1 (enExample)
SG (1) SG11202111773QA (enExample)
WO (1) WO2020152226A1 (enExample)
ZA (1) ZA202107346B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3939578A1 (en) * 2020-07-13 2022-01-19 Novaremed Ltd. Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
WO2026037478A1 (en) 2023-08-11 2026-02-19 Novaremed AG (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013084238A1 (en) * 2011-12-08 2013-06-13 Novaremed Ltd. Isolated stereoisomeric forms of (s) 2-n (3-o-(propan 2-ol) -1-propyl-4-hydroxybenzene) -3-phenylpropylamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7642290B2 (en) 2002-10-03 2010-01-05 Novaremed Limited Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
US7674829B2 (en) 2004-03-26 2010-03-09 Novaremed Limited Compounds for the treatment of AIDS and other viral diseases
GB0804213D0 (en) 2008-03-06 2008-04-16 New Era Biotech Ltd A method of printing or preventing pain
WO2011030205A1 (en) 2009-09-09 2011-03-17 Novaremed Ltd. N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation
US8802734B2 (en) 2009-09-09 2014-08-12 Novaremed Limited Method of treating or preventing pain
GB0916073D0 (en) 2009-09-14 2009-10-28 Cintec Int Ltd Improvements in and relating to building anchor systems

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013084238A1 (en) * 2011-12-08 2013-06-13 Novaremed Ltd. Isolated stereoisomeric forms of (s) 2-n (3-o-(propan 2-ol) -1-propyl-4-hydroxybenzene) -3-phenylpropylamide

Also Published As

Publication number Publication date
PT3860582T (pt) 2022-07-08
ES2913977T3 (es) 2022-06-07
KR20210119403A (ko) 2021-10-05
SG11202111773QA (en) 2021-11-29
US20220002228A1 (en) 2022-01-06
CA3118996A1 (en) 2020-07-30
US11891350B2 (en) 2024-02-06
JP7611148B2 (ja) 2025-01-09
JP2025036479A (ja) 2025-03-14
RS63270B1 (sr) 2022-06-30
EP3860582A1 (en) 2021-08-11
IL282718A (en) 2021-06-30
PL3860582T3 (pl) 2022-08-01
JP2022518288A (ja) 2022-03-14
ZA202107346B (en) 2023-10-25
BR112021019476A2 (pt) 2021-11-30
EP3860582B1 (en) 2022-05-04
CN113329746A (zh) 2021-08-31
IL282718B1 (en) 2024-04-01
WO2020152226A1 (en) 2020-07-30
IL282718B2 (en) 2024-08-01
CN113329746B (zh) 2025-05-02
AU2020210831A1 (en) 2021-05-20
DK3860582T3 (da) 2022-05-23

Similar Documents

Publication Publication Date Title
JP5371790B2 (ja) 睡眠および認知に関するうつ病における残存症状の治療のための組み合わされたセロトニン再取り込み、５−ｈｔ３および５−ｈｔ１ａ活性を有する化合物としての１−［２−（２，４−ジメチルフェニルスルファニル）フェニル］ピペラジン
JP5841636B2 (ja) Ｓｅｒｔ、５−ｈｔ３および５−ｈｔ１ａの組み合わせた活性を有する化合物の治療的使用
JP5921539B2 (ja) 下肢静止不能症候群を治療する方法
JP2025036479A (ja) 疼痛、炎症および／または自己免疫の処置または予防における使用のための化合物
TWI441630B (zh) 曲馬朵（Ｔｒａｍａｄｏｌ）和可舒葆（Ｃｏｘｉｂ）之共結晶物
EP2475361B1 (en) N-substituted benzenepropanamides for use in the treatment of pain and inflammation
JP2011506353A (ja) セロトニントランスポーター、セロトニン受容体およびノルアドレナリントランスポーターに親和性を有する化合物の治療的使用
HK40061961B (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
HK40061961A (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
TW202515540A (zh) 使用三重再攝取抑制劑治療睡眠障礙之方法
WO2026037478A1 (en) (s,s)-(3-o-(propan-2-ol)-2-amino-prop-1-yl-4-hydroxybenzene and its analogues for the treatment of chronic pain
EP2353594A1 (en) Compositions comprising tramadol and the co-crystal of celecoxib and L-proline in the treatment of pain
WO2014164784A1 (en) Hdac inhibitor polymorphic forms and methods of use
HK1156248A (en) Therapeutic uses of compounds having combined sert, 5-ht3, and 5-ht1a activity
HK1173380B (en) Co-crystals of tramadol and coxibs

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: NOVAREMED AG

Free format text: FORMER NAME(S): NOVAREMED LTD.

FGA Letters patent sealed or granted (standard patent)